BBHC
TVTX icon

Brown Brothers Harriman & Co’s Travere Therapeutics TVTX Stock Holding History

Brown Brothers Harriman & Co’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.86K Buy
332
+93
+39% +$2.78K ﹤0.01% 1360
2025
Q4 		$9.13K Buy
+239
New +$7.77K ﹤0.01% 1355

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Brown Brothers Harriman & Co's TVTX Position: Q1 2026 in Review

Brown Brothers Harriman & Co increased its Travere Therapeutics (TVTX) stake by 39% in Q1 2026, buying an estimated $2.78K and bringing the position to 332 shares worth $9.86K. The position accounts for ﹤0.01% of the portfolio, ranked #1360.

Brown Brothers Harriman & Co first reported a position in TVTX in Q4 2025 and has held it in 2 quarters since. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Brown Brothers Harriman & Co held 332 shares of Travere Therapeutics worth $9.86K as of Q1 2026.
  • Brown Brothers Harriman & Co bought 93 Travere Therapeutics shares in Q1 2026, an estimated $2.78K.
  • Travere Therapeutics made up ﹤0.01% of Brown Brothers Harriman & Co's portfolio in Q1 2026, its #1360 holding.
  • Brown Brothers Harriman & Co first reported a position in Travere Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Brown Brothers Harriman & Co's 13F filing for Q1 2026, filed 14 May 2026.